CH ENERGY ENG (03996) subsidiary wins the bid for the reclamation project of the yacht research and manufacturing project at Jinwan Yacht Industry Park in Zhuhai, including surveying, design, and construction.
China Energy Construction (03996) has announced that its subsidiary, China Gezhouba Group Three Gorges Construction Project, recently...
CH ENERGY ENG (03996) announced that its subsidiary, China Gezhouba Group Three Gorges Construction Engineering Co., Ltd. (Gezhouba Three Gorges Construction), as the lead member of a consortium, has won the bid for the marine survey and design construction general contract project for the yacht research and manufacturing project at the Jinwan Yacht Industry Park in Zhuhai. The project includes marine filling and related infrastructure construction, such as offshore dike construction, land formation, river channel excavation, and shore protection engineering. The project has a total construction period of approximately 1395 days and a bid amount of approximately RMB 15.096 billion, with the company's share amounting to approximately RMB 14.497 billion.
Related Articles
Dongfang Electric Corporation (01072) plans to offer a 7.98% discount on the sale of 68 million shares, with a net raise of approximately 1.075 billion Hong Kong dollars.

WEIMOB INC (02013) plans to discount approximately 8.87% of the total issued shares of 6.88 billion subscription shares, raising approximately 1.55 billion HKD.

ASCLETIS-B (01672) reported the latest breakthrough research on the novel fatty acid synthase (FASN) inhibitor Dehexastat (ASC40) for the treatment of acne in a dedicated session at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting.
Dongfang Electric Corporation (01072) plans to offer a 7.98% discount on the sale of 68 million shares, with a net raise of approximately 1.075 billion Hong Kong dollars.
WEIMOB INC (02013) plans to discount approximately 8.87% of the total issued shares of 6.88 billion subscription shares, raising approximately 1.55 billion HKD.

ASCLETIS-B (01672) reported the latest breakthrough research on the novel fatty acid synthase (FASN) inhibitor Dehexastat (ASC40) for the treatment of acne in a dedicated session at the 2025 European Academy of Dermatology and Venereology (EADV) annual meeting.
